GOLD (Global Oncologic Learnings for Dovitnib) Trials | GOLDTrials.com

GOLD Trials

GOLD TRIALS

Home
GOLD TRIALS

The GOLD (Global Oncologic Learnings for Dovitinib) Trials are a series of global initiatives led by Novartis that encompass a broad range of malignancies, such as renal cell carcinoma (RCC), breast cancer, gastric cancer, hepatocellular carcinoma (HCC), multiple myeloma, and urothelial cancer. Through this program, Novartis Oncology is conducting clinical studies of dovitinib (TKI258) as a single agent and in combination with other agents.¹

RCC >>

REFERENCE

Data on file. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.

Disclaimer:

This is an international Web site for GOLD Trials. The information on this site is not country-specific and may contain GOLD Trials information that is different from where you practice. Please contact your local Novartis Medical Science Liaison for the latest GOLD Trials information specific to your country.

Dovitinib (TKI258) is an investigational agent. Efficacy and safety have not been established. There is no guarantee that this compound will become commercially available.

Disclaimer:

Dovitinib (TKI258) is an investigational agent. Efficacy and safety have not been established. There is no guarantee that this compound will become commercially available.